Lux Capital Closes $1.5B Fund for "Deep Tech" Startups

  lux-capital-closes-1-5b-fund-for-deep-tech-startups.html
  Business and Finance on Wed, Jan 07th, 2026 by TechCrunch
      Locale: UNITED STATES

New York, NY - January 8th, 2026 - Lux Capital, a leading venture capital firm specializing in science-based startups, today announced the successful closing of its seventh fund, Lux Venture Capital Fund VII, with a substantial $1.5 billion in commitments. This marks the firm's largest fund to date, significantly surpassing its $1.2 billion raise in 2020 and signaling a strong and continuing investor appetite for what's become known as "deep tech" - companies tackling foundational, complex challenges in areas like artificial intelligence, biotechnology, robotics, and advanced materials.

The new fund's size reflects a broader trend in the venture capital landscape: a shift toward investing in companies with significant technological barriers to entry, and the potential for disruptive innovation. While software-focused startups dominated investment for much of the past decade, investors are now increasingly recognizing the long-term potential of businesses building on fundamental scientific breakthroughs. Lux Capital, founded in 2012, has established itself as a key player in this evolving market, boasting a portfolio that includes high-profile successes like SpaceX, Ginkgo Bioworks, and Locus Robotics. These aren't incremental improvements; they're companies actively reshaping industries.

"The landscape has changed," explains Dr. Anya Sharma, a principal at rival firm Nova Ventures, specializing in materials science. "For years, it was easier - and faster - to see returns from scaling a compelling user experience. Now, those low-hanging fruits are largely picked. To achieve truly exponential growth, investors are looking for companies building real, defensible technology. Lux Capital has been ahead of this curve for some time."

Lux Capital's approach isn't simply about writing checks. The firm emphasizes the crucial role of its in-house team of scientists, engineers, and traditional investors. This unique blend allows them to deeply understand the technical complexities of potential investments, accurately assess risks, and provide valuable support to portfolio companies beyond just capital. This ability to conduct thorough due diligence on technologies that require specialized expertise is a significant differentiator.

"We're not just financial analysts looking at spreadsheets," said Josh Wolfe, a managing partner at Lux Capital, in a prepared statement. "We're actively engaging with the science, understanding the engineering challenges, and collaborating with founders to navigate the path to commercialization. We've been building this expertise for over a decade."

The fund's investment strategy appears to be focused primarily on early-stage companies, particularly at the Series A and Series B funding rounds. This indicates a willingness to take on greater risk in exchange for potentially higher returns, and to actively shape the direction of these nascent businesses. While Lux Capital will likely participate in later funding rounds of successful portfolio companies, the core focus remains on identifying and nurturing promising ventures at their earliest stages.

Analysts predict that the $1.5 billion fund will be deployed over the next several years, with a significant portion allocated to sectors experiencing rapid innovation, such as generative AI and personalized medicine. The increased investment in biotech is particularly noteworthy, given the ongoing advancements in gene editing, drug discovery, and synthetic biology. Robotics, driven by breakthroughs in computer vision and machine learning, also remains a key area of interest.

The closing of Lux Venture Capital Fund VII is more than just a financial transaction; it's a vote of confidence in the power of science and engineering to solve some of the world's most pressing problems. It underscores the growing recognition that sustained economic growth will increasingly depend on innovations rooted in fundamental scientific research and technological advancement. The performance of this fund will undoubtedly be closely watched by other venture capital firms and investors as they navigate the evolving landscape of deep tech investment.